2Q26 Private Biotech Financing Review - with updated tracker

研报英文原文证据摘录

2Q26 Private Biotech Financing Review - with updated tracker

M Equity In P1, Patients Small molecule programs targetting NAD+ utilizing enzymes from BEACONinhibitorsplatforminitially.across oncology and immunology indications -- focused on PARP7 and PARP14 MA Cambridge, MA Pfizer

2/1/23 Ratio Therapeutics $20M A Not Specified 2 R&DFirstplatforms,program targetsTrillium,FAPwhichin STS;is atargetsPK modulationfor otherplatformindicationsthatnotcandisclosed.be altereddiagnostic.Ac225to bindandtoLu177any antigen-specificisotopes used. Alsotargethasanda FAPMacropa,diangosticwhichprogramis a Actinium-225and Granzymechelator.B MA Boston, MA Duquesne Capital Schusterman Family Investments Kenan Turnacioglu

2/2/23 Pherin Pharmaceuticals Not Specified M&A In P3 Acquired by Vistagen (Nasdaq: VTGN) - Pherin is focusedand P2 foron adjustmentneuropsychiatricdisorderandwithneuroendocrineanxiety. PH10conditions.in dev for MDD.PH94B (fasedienol nasal spray) lead asset in P3 for SAD

2/2/23 Immunorizon $100M M&A Not Specified Purple Biotech acquires Immunorizonasset adds toforPurple's100M totalportfoliodeal consistingvalue. Immunorizonof NT219 (STAT3/is developingIRS-1 degrader)tri-specificandantibodyCM24 (calciumthat engageschannelT cellsinhibitor).and NK cells for solid tumors. The Israel Tel Aviv

2/6/23 IgGenix $40M B In P1, Patients basicallyIsolates andtookre-engineershigh-affinityfullyIgE vshuman,peanutshigh-affinity,from humans,allergen-specificthen Workingre-engineeredIgGon otherantibodiesit toantigens/allergiesbe IgG4designedinstead,to blockasthuswell.ableand topreventbind thethepeanutallergicallergenscascade. withoutWith leadactivatingprogrammastIGNX001,cells. CA San Francisco, CA Alexandria Venture Investments Eli Lilly and Company Khosla Ventures